How cagrilintide affects hunger and eating in overweight adults
Treatments studied
Part of Hormones & metabolism clinical trials.
This early-stage study tests a new medication called cagrilintide to see how it influences appetite and food intake in adults with overweight or obesity. Researchers want to understand if this drug could help people feel fuller and eat less.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old
- Your BMI (a measure of weight relative to height) is 27 or higher, and your extra weight is from body fat, not muscle
- You are generally healthy except for being overweight or obese—no serious heart, lung, kidney, liver, or digestive problems
- Your blood sugar control is normal (HbA1c below 6.5%), and you do not have diabetes
- You have not tried to lose weight, joined a weight-loss program, or significantly changed your weight (5% or more) in the past 3 months
- You are not currently taking weight-loss drugs, insulin-like medications, or certain psychiatric or steroid medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests different formulations of cagrilintide, a new medication, to see how the body absorbs and processes each version. Cagrilintide may help with weight management. Researchers will measure blood levels after you receive multiple doses.
This study tests an experimental drug (NNC0487-0111) to see how it changes food intake, appetite, and the way your body processes food after meals. It is for adults with obesity who do not have diabetes.
This study tests a new injectable medication called cagrilintide for people with obesity who had to stop GLP-1 drugs (like Ozempic or Wegovy) because of stomach problems. The goal is to see if cagrilintide causes fewer stomach side effects while still helping with weight.
This study compares two different versions of an investigational weight-loss medication (cagrilintide) against a placebo to see which is more effective and safe for people with excess weight. Participation involves receiving injections and regular check-ins to monitor your progress.
This trial tests whether cagrilintide, a medicine similar to a natural hormone called amylin, can affect bone health. It is for postmenopausal women with obesity who do not have bone disease or other conditions affecting bone metabolism.
This trial tests two new medicines (cagrilintide and CagriSema) to see if they help children and teens lose weight. It's for young people who have tried lifestyle changes without enough success.
Hear when a new Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.